Poster 17: PERSONALIZED DIAGNOSIS AND MANAGEMENT OF BCR-ABL POSITIVE AND
NEGATIVE CHRONIC MYELOPROLYPHERATIVE NEOPLASMS
Vasile Musteata, Ivan Negara, Larisa Musteata
Poster 18: CHRONIC MYELOGENOUS LEUKEMIA ON TYROSINE KINASE INHIBITORS-
HEMATOLOGICAL CHANGES AND CORRELATION WITH EUROPEAN LEUKEMIA
NETWORK RESPONSE CRITERIA
Shano Naseem, Karthik Bommannan, Neelam Varma, Pankaj Malhotra, Subhash
Varma
Poster 19: LONG-TERM EFFECT OF RUXOLITINIB IN INADEQUATELY CONTROLLED
POLYCYTHAEMIA VERA WITHOUT SPLENOMEGALY: 5-YEAR RESULTS FROM
THE PHASE 3 RESPONSE-2 STUDY
Francesco Passamonti, Francesca Palandri, Guray Saydam, Miklós Egyed, Jeannie
Callum, Timothy Devos, Serdar Sivgin, Paola Guglielmelli, Alessandro M. Vannucchi,
Evren Zor, Mike Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Griesshammer
Poster 20: A RARE CASE OF ASYMPTOMATIC SYSTEMIC MASTOCYTOSIS WITH
ASSOCIATED HAEMATOLOGICAL NEOPLASM LEADING TO BUDD CHIARI
SYNDROME
Iman Qureshi, Hayder Hussein
Poster 21: A CASE REPORT OF RECURRENT TKI-INDUCED PANCREATITIS IN A PATIENT
WITH CHRONIC MYELOID LEUKEMIA
Shane Reeves, Gregory Monohan
Poster 22: JAK2 NEGATIVE POLYCYTHEMIA VERA: A RARE AND MANAGEABLE
DIAGNOSIS
Ana Rolo, Maria Eduarda Couto, Thales Millet, Teresa Braga, Isabel Oliveira, Nelson
Domingues, Susana Bizarro, Susana Lisboa, Manuel Teixeira, José Mariz
Poster 23: VISUAL ABNORMALITIES AS THE FIRST SYMPTOM IN CHRONIC MYELOID
LEUKAEMIA
Christopher J. Saunders, Catarina Xavier, Filipa Saraiva, Paula Sousa e Santos, Patrícia
Ribeiro
Poster 24: UNCOMMON CUTANEOUS TOXICITY ASSOCIATED TO PROLONGED USE OF
HYDROXYUREA IN A PATIENT WITH POLYCYTHEMIA VERA
Fernanda Seganfredo, Joana Desterro, Francesca Pierdomenico, Maria Gomes da Silva
Poster 25: VENETOCLAX-PONATINIB BASED TREATMENT IN REFRACTORY BLASTIC
PHASE OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WITH SARS-COV-2-
INFECTION
Fernanda Seganfredo, Diana Viegas, Joana Desterro, Francesca Pierdomenico, Maria
Gomes da Silva
Poster 26: DEVELOPMENT OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WITH CALR-MUTATED
PRIMARY MYELOFIBROSIS
Patryk Sobieralski, Maria Bieniaszewska, Jan Zaucha
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES